Vitamin D shows potential insulin-sparing effect in young type 1 diabetes patients but lacks conclusive evidence for glycaemic control

A new review suggests vitamin D supplementation may reduce insulin requirements in children and adolescents with type 1 diabetes, but current evidence does not support its use as a universal treatment to improve blood sugar control.

A new review of paediatric type 1 diabetes trials suggests vitamin D may ease one part of the daily burden of the disease without clearly changing the disease itself. Writing in BMC Endocrine Disorders, Chunli Zhang and colleagues reported on 4 September 2026 that, across nine randomised controlled trials involving 370 children and adolescents, vitamin D supplementation was linked to a statistically significant fall in total daily insulin dose of 0.13 units per kilogram a day. (link.springer.com)

That signal came with important limits. The same review found no meaningful improvement in HbA1c, the main laboratory measure of longer-term glucose control, and no clear preservation of fasting or stimulated C-peptide, which are used to judge how much insulin the pancreas is still making. The authors also found no convincing shift in inflammatory or immune markers, and said larger, better-designed trials, especially in newly diagnosed patients with residual beta-cell function, are still needed. The review searched five major databases through 14 October 2025 and the authors said the evidence should be read as suggestive rather than practice-changing. (link.springer.com)

That caution fits the wider literature. A 2022 systematic review indexed by PubMed screened 1,613 papers and included 10 studies, of which eight were clinical trials. Half of the studies reported an improvement in HbA1c after vitamin D supplementation, but only one of those positive studies was judged methodologically strong. Its conclusion was blunt: there was not yet consistent evidence that vitamin D improved glycaemic control as an add-on treatment for children and adolescents with type 1 diabetes. (pubmed.ncbi.nlm.nih.gov)

Some of the more hopeful findings have come in children who were only recently diagnosed and still in the so-called honeymoon phase, when some insulin production remains. In Frontiers in Endocrinology in August 2022, Benjamin Udoka Nwosu described a double-blind trial in 36 children and adolescents given high-dose ergocalciferol or placebo. The regimen used 50,000 international units a week for two months and then every other week for 10 months. Nwosu reported a slower rise in HbA1c in the vitamin D group, at 0.14 percentage points every three months against 0.46 in placebo, and a better insulin-dose adjusted HbA1c, a marker used to track partial remission. He argued that clinicians should “begin vitamin D supplementation if serum 25(OH)D concentration is <30 ng/mL”. (frontiersin.org)

But older interventional work also shows why the new meta-analysis does not settle the question. In a randomised crossover study published in Pediatric Diabetes, Erin Shih and colleagues followed 25 adolescents aged 13 to 21, 62% of them female and 62% Hispanic, all of whom had vitamin D deficiency. They received 20,000 IU of vitamin D3 a week for six months, which raised average serum 25-OH vitamin D from 22 to 34.3 ng/mL. Even so, the treatment did not change HbA1c, insulin dose, C-reactive protein, interleukin-6 or TNF-α. (pubmed.ncbi.nlm.nih.gov)

Part of the reason vitamin D keeps returning to the agenda is that deficiency appears to be common in this population. In 2016, a University of Pennsylvania School of Nursing team led by Terri Lipman reported on about 200 children and adolescents treated at the Children’s Hospital of Philadelphia. The group found a high prevalence of low 25-hydroxyvitamin D even among healthy-weight and white children, groups often assumed to be at lower risk. Lipman and colleagues said their work was the first adequately powered study to examine the link with HbA1c in this population and concluded: “These data suggest the need for monitoring of vitamin D in all youth with this disorder.” (newswise.com)

Current guidance remains more restrained than the latest headline might imply. A 2024 paediatric type 1 diabetes nutrition guideline says vitamin D insufficiency or deficiency may affect as many as 63% of patients and recommends screening at stage I autoimmunity or at first onset of symptoms. It also suggests prescribing cholecalciferol or ergocalciferol to correct deficiency or insufficiency, but grades that advice as Level 2(C), conditional. The same document says the effect of supplementation on glycaemic management is still inconclusive, drawing a line between correcting a common deficiency and claiming a proven diabetes-modifying therapy. (andeal.org)

What the new evidence adds, then, is not proof that vitamin D can preserve beta cells or improve blood sugar control across the board, but a renewed case that it may have an insulin-sparing role in some young patients. That is potentially useful because insulin dose matters to families managing injections, pumps and the risk of hypoglycaemia every day. Yet the mixed trial record, the absence of a clear HbA1c benefit in the pooled data, and the cautious wording of current guidance all point the same way: vitamin D is moving closer to the centre of the discussion in paediatric type 1 diabetes, but it has not yet earned a place as a universal add-on treatment beyond correcting deficiency. (link.springer.com)